Otsuka's Two Core Businesses

Helping to cure disease and protect health
— a holistic healthcare company concerned about the entire body

Pharmaceutical Business

Providing Breakthrough Treatments for Patients Around the World

Otsuka Pharmaceutical is dedicated to the research & development of highly-innovative drugs and diagnostics. Leveraging our research culture of curiosity, determination and unconventional thinking, we strive for solutions that only Otsuka can deliver, to improve the health of people across the world.
Our R&D philosophy places emphasis on encouraging individual researchers to take the untraveled path, pursuing fresh ideas within a collaborative, accommodating environment. Supported by the global integration of our research and development institutes in Asia, the US and Europe, the result has been epoch-making drugs in the following fields.

Central Nervous System (CNS): The antipsychotic drug ABILIFY, which is available in 60 countries and regions, has reached 7th place*1 in the global ranking of drug sales. In the US, growing prescriptions for bipolar disorder and as an adjuvant therapy for major depression pushed ABILIFY to the top sales position*2 among prescription drugs. On April 1, 2013, Otsuka began co-promotion of ABILIFY in Europe with H. Lundbeck A/S.
Marketing of Abilify Maintena, a once-monthly extended-release injection, began in the US in March 2013, as a new treatment option for schizophrenia, building on the success of ABILIFY. This was soon followed by the launch of marketing in Europe, and as of February 2015, the product is being sold in 18 European countries including the UK. In September 2014, marketing approval was obtained from the US Food and Drug Administration (FDA) for a new injectable formulation of Abilify Maintena in a ready-to-use prefilled syringe (the new pre-filled dual chamber syringe kit).
Otsuka acquired Avanir Pharmaceuticals, Inc. of the US in January 2015. The aim is to make a full-scale entry into the neurologic disease area, and also build upon the Otsuka’s presence in the psychiatric disease area and core business presence in the CNS field. In the US, Avanir sells NUEDEXTA, the world’s first and only approved treatment for the neurologic disease pseudobulbar affect (PBA). It is also engaged in the development of therapeutic agents in the neurologic disease field, such as agents for Alzheimer’s type dementia, and for Parkinson’s disease. Otsuka will continue to expand its business into the neurologic disease area, aiming to improve on the low treatment satisfaction in this area.

Oncology: Busulfex, the only drug approved by the US FDA for the conditioning regimen prior to hematopoietic progenitor cell transplantation, is now available in over 50 countries through Otsuka Pharmaceutical and its partners. It has become a standard treatment replacing radiotherapy within the bone marrow transplantation regimen. In December 2014, Otsuka signed an agreement with ARIAD Pharmaceuticals, Inc. to commercialize ARIAD’s treatment for resistant and intolerant chronic myeloid leukemia in Japan and nine other Asian countries*3 and regions, and to fund future clinical trials in those countries.

Cardiovascular: The vasopressin V2 receptor antagonist Samsca, which is now available in 20 countries and regions, has achieved good penetration in medical settings thanks to the new value and utility it provides as an oral aquaretic drug. In 2014, the world’s first approval of a treatment for autosomal dominant polycystic kidney disease (ADPKD), an intractable disease with no treatments until now, was obtained for Samsca in Japan. In 2015, approval recommendations of JINARC (global product name) were obtained in Canada as well as in Europe from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency.

Ophthalmology: Long- term prescriptions are now available for Mucosta ophthalmic suspension UD2%, a dry eye treatment that repairs the mucous membrane of the eye and promotes mucin production.

*1
©2015 IMS Health, All rights reserved. Estimated based on “World Review Preview 2014 (Year 2014 Sales Data).” Reprinted with permission.
*2
©2015 IMS Health, All rights reserved. Estimated based on “MIDAS Quantum 4Q/2013 Sales data.” Reprinted with permission.
*3
Japan, China (including Hong Kong), Indonesia, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam

As of March 2015

Nutraceutical Business*1

Helping Healthy People Become Even
Healthier

Otsuka develops and delivers innovative products, based on cutting-edge science, to maintain and promote peoples' health around the world. Our nutraceutical business has defined and developed totally new markets in unique ways, as we communicate the value of our products to consumers, including in person.

As of December 2016, water an d ion replenishment drink POCARI SWEAT is sold in 20 countries and regions. Launched in Japan in April 2013, POCARI SWEAT ION WATER, a clean-tasting beverage that’s not overly sweet, offers all the functional benefits of POCARI SWEAT. Delicious even at room temperature, POCARI SWEAT ION WATER is pioneering a market as a rehydration beverage to be enjoyed in the course of daily activities.

ORONAMIN C DRINK, a unique carbonated nutritional drink for everyday consumption, marked its 50th anniversary in 2015. This refreshing vitamin drink continues to energize people of all ages in nine countries and regions around the world*2.

In 2016, the Calorie Mate lineup of balanced nutrition food products was expanded with the addition of three flavors of Calorie Mate Jelly. As eating styles diversify, Calorie Mate is a nutritionally balanced brand, offering effortless consumption of five major nutrients by anyone, anywhere, at any time.

Otsuka Pharmaceutical has focused on the creation of new soy products and winning new customers based on the concept of “Soylution*3” – the idea that soy can provide solutions to human health and environmental issues. The first brand under this innovative concept, the SOYJOY line of baked soy bars was expanded with the 2016 introduction of three flavors of SOYJOY Crispy, featuring the light, crunchy texture and delicious flavor of puffed soy. This was followed by the introduction of SOYJOY Crispy White Macadamia in 2017, providing yet another delicious way to obtain the nutritional benefits of whole soy.

Focusing on the advantages of equol, produced when soy isoflavones are metabolized by intestinal bacteria, Otsuka Pharmaceutical released EQUELLE in April 2014. Containing equol derived from soybeans, this easy-to-take supplement helps support women’s health and beauty.

In accordance with government guidelines for Foods for Specified Health Uses (FOSHU) and the new Foods with Function Claims system introducedin 2016, easy-to-understand labeling contributes to consumer safety and facilitates appropriate product selection. The Otsuka Pharmaceutical selection of Foods for Specified Health Uses includes Fibe-Mini dietary fiber beverage to promote intestinal function and Kenja-no Shokutaku*4 Double Support, which slows the body’s post-meal absorption of sugar and lipids.

Otsuka markets seven products with labeling as Foods with Function Claims. This includes five products from the Nature Made series of vitamins and supplements: Ginkgo Biloba for improvement of memory acuity, Lutein to support contrast sensitivity (eye’s ability to distinguish light and dark), Astaxanthin to support the eye’s ability to focus, and Super Fish Oil and Fish Oil Pearl for inhibition of triglyceride levels in the blood. In the OMUGI SEIKATSU (Barley Life) line, Omugi Gohan and Omugi Gohan Japanese-Style offer convenient ways to consume the water-soluble dietary fiber of barley beta-glucans.

In the Cosmedics*5 business dedicated to healthy skin, the 2015 launch of Medicated Skin Whitening expanded the UL•OS brand of men’s skincare products. Currently consisting of 16 products in eight categories, UL•OS is growing steadily as a familiar brand offering comprehensive, head-to-toe skincare.

*1
Nutraceuticals: nutrition + pharmaceuticals
*2
Countries and regions where ORONAMIN C DRINK is sold: Japan, UAE, Kuwait, Bahrain, Oman, Saudi Arabia, Qatar, South Korea, Hong Kong
*3
Soylution: Soy + solution
*4
Wise man's dining in Japanese
*5
Cosmedics: cosmetics + medicine

As of January 1, 2017